GUSHENGTANG (02273) rose nearly 5%, gaining 4.46% to close at HK$33.7 with trading volume of HK$68.85 million as of press time.

On the news front, the "Intelligent Innovation-Driven High-Quality Development of Traditional Chinese Medicine and GUSHENGTANG National Medicine AI System Launch Conference" was recently held in Guangzhou. At the conference, GUSHENGTANG demonstrated the phased achievements of its "Traditional Chinese Medicine + AI" strategy through the major launch of its National Medicine AI System and ecosystem partnership signings, further consolidating the company's leading position in the intelligent traditional Chinese medicine field.

Haitong International noted that according to public earnings calls, management expects AI products to achieve large-scale commercial monetization in 2025, with continued efforts in four key areas: providing scarce physician resources; training young physicians; improving user satisfaction; and accelerating traditional Chinese medicine's global expansion.

CITIC Securities International stated that GUSHENGTANG launched its first "National Medicine AI Avatar" in June 2025, and by August had released a total of 10 "National Medicine AI Avatars" covering eight core traditional Chinese medicine specialties including oncology, dermatology, gastroenterology, otolaryngology, andrology, psychology and sleep medicine, classical prescription medicine, and orthopedics and traumatology. Through AI technology empowering traditional Chinese medicine, the company increases the supply of high-quality TCM services, addresses the shortage of quality medical resources, and provides standardized and efficient diagnostic and treatment experiences for more patients. Additionally, the company launched an AI health assistant to further enhance patient-side diagnostic and treatment experiences.